Technical Analysis for ALBT - Avalon GloboCare Corp.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.32 | 5.79% | 0.02 |
ALBT closed up 5.79 percent on Thursday, March 28, 2024, on 2.74 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Earnings Movers | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Boomer Sell Setup | Bearish Swing Setup | 5.79% | |
Narrow Range Bar | Range Contraction | 5.79% | |
Inside Day | Range Contraction | 5.79% |
Alert | Time |
---|---|
20 DMA Resistance | about 8 hours ago |
Rose Above 20 DMA | about 8 hours ago |
2x Volume Pace | about 8 hours ago |
1.5x Volume Pace | about 8 hours ago |
3x Volume Pace | about 8 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/28/2024
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Sector: Healthcare
Industry: Medical Care
Keywords: Medicine Clinical Medicine Immunotherapy Cell Therapy Exosome Bioproduction Vesicles
Classification
Sector: Healthcare
Industry: Medical Care
Keywords: Medicine Clinical Medicine Immunotherapy Cell Therapy Exosome Bioproduction Vesicles
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.44 |
52 Week Low | 0.25 |
Average Volume | 179,709 |
200-Day Moving Average | 0.79 |
50-Day Moving Average | 0.38 |
20-Day Moving Average | 0.35 |
10-Day Moving Average | 0.32 |
Average True Range | 0.03 |
RSI (14) | 39.39 |
ADX | 36.58 |
+DI | 15.73 |
-DI | 24.98 |
Chandelier Exit (Long, 3 ATRs) | 0.35 |
Chandelier Exit (Short, 3 ATRs) | 0.35 |
Upper Bollinger Bands | 0.44 |
Lower Bollinger Band | 0.27 |
Percent B (%b) | 0.29 |
BandWidth | 45.61 |
MACD Line | -0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.0035 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.39 | ||||
Resistance 3 (R3) | 0.40 | 0.38 | 0.38 | ||
Resistance 2 (R2) | 0.38 | 0.36 | 0.38 | 0.38 | |
Resistance 1 (R1) | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 |
Pivot Point | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 |
Support 1 (S1) | 0.30 | 0.31 | 0.30 | 0.30 | 0.27 |
Support 2 (S2) | 0.28 | 0.30 | 0.28 | 0.26 | |
Support 3 (S3) | 0.25 | 0.28 | 0.26 | ||
Support 4 (S4) | 0.25 |